In 2010, Practical Radiation Oncology (PRO) published an editorial by Loo et al, that introduced the terminology stereotactic ablative radiotherapy, for which they contrived the acronym SABR (not SAR, or SART, as one might have anticipated). Their stated premise included several opinions: a perceived difficulty in finding an appropriate nomenclature to define the emerging literature and practice of precisely targeted, high-dose, hypofractionated radiation therapy; what they believed to be lack of precision in the then operative and established terminology of stereotactic body radiation therapy (SBRT) to describe the “extreme dose intensity” (their words) being employed; that SBRT did not connote “ablative,” and; then in an ostensibly commercial turn, that the acronym SBRT was not cool (our word) enough.